Cargando…

Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE

SUMMARY: Early PINP changes correlate with 18-month lumbar spine BMD changes and the correlation was greater with abaloparatide versus teriparatide. The uncoupling index was similar between the two agents. INTRODUCTION: We evaluated the relationship between early PINP changes and subsequent changes...

Descripción completa

Detalles Bibliográficos
Autores principales: Eastell, R., Mitlak, B. H., Wang, Y., Hu, M., Fitzpatrick, L. A., Black, D. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422956/
https://www.ncbi.nlm.nih.gov/pubmed/30635696
http://dx.doi.org/10.1007/s00198-018-04819-1
_version_ 1783404448743161856
author Eastell, R.
Mitlak, B. H.
Wang, Y.
Hu, M.
Fitzpatrick, L. A.
Black, D. M.
author_facet Eastell, R.
Mitlak, B. H.
Wang, Y.
Hu, M.
Fitzpatrick, L. A.
Black, D. M.
author_sort Eastell, R.
collection PubMed
description SUMMARY: Early PINP changes correlate with 18-month lumbar spine BMD changes and the correlation was greater with abaloparatide versus teriparatide. The uncoupling index was similar between the two agents. INTRODUCTION: We evaluated the relationship between early PINP changes and subsequent changes in spine BMD following abaloparatide and teriparatide treatments. We also explored the use of an “uncoupling index” (UI), the balance between bone formation and bone resorption, which we hypothesised would be similar in response to these treatment groups. METHODS: Blood samples were taken for measurement of bone turnover markers (BTMs) s-PINP and s-CTX at baseline, 1, 3, 6, 12, and 18 months from 189 abaloparatide patients and 227 teriparatide patients randomly selected from all participants who completed the study. BMD was measured by DXA at baseline, 6, 12, and 18 months. Correlations were calculated between log ratio of BTMs from baseline to 3 months and percent change from baseline in BMD at 18 months. A UI was calculated using log transformation and subtraction of the standard deviate for s-CTX from the standard deviate for s-PINP for each patient. RESULTS: Early BTM changes were associated with subsequent BMD changes for both treatments. Pearson correlations for the log ratio of PINP over baseline at 3 months and BMD percent change from baseline at 18 months were larger (P < 0.0001) with abaloparatide (r = 0.561) than teriparatide (r = 0.198). The mean UI at 1 month was greater for abaloparatide versus teriparatide (1.743 and 1.493, respectively; P = 0.03) but was similar at 3 months or later time points. CONCLUSIONS: Early s-PINP changes correlate with percentage change in lumbar spine BMD 18 months after treatment with both abaloparatide and teriparatide, though the correlation with abaloparatide was greater. The UI was similar between abaloparatide and teriparatide suggesting that the balance between formation and resorption markers was similar.
format Online
Article
Text
id pubmed-6422956
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer London
record_format MEDLINE/PubMed
spelling pubmed-64229562019-04-05 Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE Eastell, R. Mitlak, B. H. Wang, Y. Hu, M. Fitzpatrick, L. A. Black, D. M. Osteoporos Int Original Article SUMMARY: Early PINP changes correlate with 18-month lumbar spine BMD changes and the correlation was greater with abaloparatide versus teriparatide. The uncoupling index was similar between the two agents. INTRODUCTION: We evaluated the relationship between early PINP changes and subsequent changes in spine BMD following abaloparatide and teriparatide treatments. We also explored the use of an “uncoupling index” (UI), the balance between bone formation and bone resorption, which we hypothesised would be similar in response to these treatment groups. METHODS: Blood samples were taken for measurement of bone turnover markers (BTMs) s-PINP and s-CTX at baseline, 1, 3, 6, 12, and 18 months from 189 abaloparatide patients and 227 teriparatide patients randomly selected from all participants who completed the study. BMD was measured by DXA at baseline, 6, 12, and 18 months. Correlations were calculated between log ratio of BTMs from baseline to 3 months and percent change from baseline in BMD at 18 months. A UI was calculated using log transformation and subtraction of the standard deviate for s-CTX from the standard deviate for s-PINP for each patient. RESULTS: Early BTM changes were associated with subsequent BMD changes for both treatments. Pearson correlations for the log ratio of PINP over baseline at 3 months and BMD percent change from baseline at 18 months were larger (P < 0.0001) with abaloparatide (r = 0.561) than teriparatide (r = 0.198). The mean UI at 1 month was greater for abaloparatide versus teriparatide (1.743 and 1.493, respectively; P = 0.03) but was similar at 3 months or later time points. CONCLUSIONS: Early s-PINP changes correlate with percentage change in lumbar spine BMD 18 months after treatment with both abaloparatide and teriparatide, though the correlation with abaloparatide was greater. The UI was similar between abaloparatide and teriparatide suggesting that the balance between formation and resorption markers was similar. Springer London 2019-01-11 2019 /pmc/articles/PMC6422956/ /pubmed/30635696 http://dx.doi.org/10.1007/s00198-018-04819-1 Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Eastell, R.
Mitlak, B. H.
Wang, Y.
Hu, M.
Fitzpatrick, L. A.
Black, D. M.
Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE
title Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE
title_full Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE
title_fullStr Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE
title_full_unstemmed Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE
title_short Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE
title_sort bone turnover markers to explain changes in lumbar spine bmd with abaloparatide and teriparatide: results from active
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422956/
https://www.ncbi.nlm.nih.gov/pubmed/30635696
http://dx.doi.org/10.1007/s00198-018-04819-1
work_keys_str_mv AT eastellr boneturnovermarkerstoexplainchangesinlumbarspinebmdwithabaloparatideandteriparatideresultsfromactive
AT mitlakbh boneturnovermarkerstoexplainchangesinlumbarspinebmdwithabaloparatideandteriparatideresultsfromactive
AT wangy boneturnovermarkerstoexplainchangesinlumbarspinebmdwithabaloparatideandteriparatideresultsfromactive
AT hum boneturnovermarkerstoexplainchangesinlumbarspinebmdwithabaloparatideandteriparatideresultsfromactive
AT fitzpatrickla boneturnovermarkerstoexplainchangesinlumbarspinebmdwithabaloparatideandteriparatideresultsfromactive
AT blackdm boneturnovermarkerstoexplainchangesinlumbarspinebmdwithabaloparatideandteriparatideresultsfromactive